Approved regulatory verdict
Evidence outlook
Approved: relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic... (FDA)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational. Regulatory approval supersedes design-level evidence grading for the approved use.
Also in development: Acute Myeloid Leukemia · Phase 2
Source for the program status
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Acute Myeloid Leukemia · investigational · Featured evidence · 5 Mantle Cell Lymphoma · not a covered market · Outside covered markets · 1 investigational Featured evidence · 5
Competitive landscape 71 competitors in this universe: 8 direct rivals (same mechanism and indication), 3 same-class, 60 same-indication; 11 further along in development.
…and 56 more. Research shows the complete landscape.
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (35 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (2) November 2026 (2) Phase 1/2 Relapsed/Refractory Multiple Myeloma Recruiting
Est. primary completion 2026-11 ·
NCT04973605 ·
CT.gov ↗ What to watch Phase 2 Chronic Lymphocytic Leukemia Active not recruiting
Est. primary completion 2026-11 ·
NCT06637501 ·
CT.gov ↗ What to watch 2027 (9) April 2027 (1) Phase 2 Chronic Lymphocytic Leukemia Not yet recruiting
Est. primary completion 2027-04-30 ·
NCT07674810 ·
CT.gov ↗ What to watch May 2027 (2) Phase 1 Mature B-Cell Malignancies Active not recruiting
Est. primary completion 2027-05-31 ·
NCT04277637 ·
CT.gov ↗ What to watch Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2027-05-31 ·
NCT07548710 ·
CT.gov ↗ What to watch August 2027 (2) Phase 2 Richter Transformation Recruiting
Est. primary completion 2027-08 ·
NCT04271956 ·
CT.gov ↗ What to watch Phase 1/2 Multiple Myeloma (MM) Not yet recruiting
Est. primary completion 2027-08-01 ·
NCT07687004 ·
CT.gov ↗ What to watch September 2027 (1) Phase 1/2 Large B-cell Lymphoma Not yet recruiting
Est. primary completion 2027-09-30 ·
NCT07638787 ·
CT.gov ↗ What to watch October 2027 (1) Phase 2 Acute Myeloid Leukemia Active not recruiting
Est. primary completion 2027-10-31 ·
NCT06497062 ·
CT.gov ↗ What to watch December 2027 (2) Phase 2 AL Amyloidosis (AL), t(11;14) Positive Recruiting
Est. primary completion 2027-12-31 ·
NCT07335887 ·
CT.gov ↗ What to watch Phase 2 Chronic Lymphocytic Leukemia Recruiting
Est. primary completion 2027-12-31 ·
NCT07671378 ·
CT.gov ↗ What to watch 2028 (11) March 2028 (1) Phase 2 Chronic Lymphocytic Leukemia Recruiting
Est. primary completion 2028-03-01 ·
NCT06849713 ·
CT.gov ↗ What to watch August 2028 (4) Phase 2 Chronic Lymphocytic Leukemia Recruiting
Est. primary completion 2028-08-01 ·
NCT06839053 ·
CT.gov ↗ What to watch Phase 2 Chronic Lymphocytic Leukemia Not yet recruiting
Est. primary completion 2028-08-13 ·
NCT07812246 ·
CT.gov ↗ What to watch Phase 1/2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2028-08-31 ·
NCT04771130 ·
CT.gov ↗ What to watch Phase 3 Mantle Cell Lymphoma, B Cell Lymphoma Recruiting
Est. primary completion 2028-08-31 ·
NCT06742996 ·
CT.gov ↗ What to watch September 2028 (2) Phase 2 Mantle Cell Lymphoma Not yet recruiting
Est. primary completion 2028-09 ·
NCT07799220 ·
CT.gov ↗ What to watch Phase 3 Chronic Lymphocytic Leukemia Recruiting
Est. primary completion 2028-09-30 ·
NCT07321652 ·
CT.gov ↗ What to watch December 2028 (4) Phase 2 MCL Recruiting
Est. primary completion 2028-12 ·
NCT06463691 ·
CT.gov ↗ What to watch Phase 1/2 B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma Recruiting
Est. primary completion 2028-12-02 ·
NCT06634589 ·
CT.gov ↗ What to watch Phase 2 Waldenstrom Macroglobulinemia Not yet recruiting
Est. primary completion 2028-12-31 ·
NCT06547866 ·
CT.gov ↗ What to watch Phase 2 Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma Not yet recruiting
Est. primary completion 2028-12-31 ·
NCT07774234 ·
CT.gov ↗ What to watch 2029 (8) January 2029 (1) Phase 1 Chronic Lymphocytic Leukemia Recruiting
Est. primary completion 2029-01-31 ·
NCT06859008 ·
CT.gov ↗ What to watch March 2029 (1) Phase 1 Intermediate-to-High-Risk Mantle Cell Lymphoma, the Efficacy and Safety Not yet recruiting
Est. primary completion 2029-03-01 ·
NCT07548255 ·
CT.gov ↗ What to watch April 2029 (1) Phase 1/2 Acute Myeloid Leukemia Not yet recruiting
Est. primary completion 2029-04-30 ·
NCT07757672 ·
CT.gov ↗ What to watch September 2029 (1) Phase 3 Chronic Lymphocytic Leukemia Recruiting
Est. primary completion 2029-09-30 ·
NCT06943872 ·
CT.gov ↗ What to watch November 2029 (2) Phase 2 Mantle Cell Lymphoma, Lymphoma Recruiting
Est. primary completion 2029-11-01 ·
NCT06854003 ·
CT.gov ↗ What to watch Phase 1/2 Chronic Lymphocytic Leukemia Recruiting
Est. primary completion 2029-11-30 ·
NCT06697184 ·
CT.gov ↗ What to watch December 2029 (2) Phase 2 CLL / SLL Not yet recruiting
Est. primary completion 2029-12-31 ·
NCT07682415 ·
CT.gov ↗ What to watch Phase 2 Mantle Cell Lymphoma Recruiting
Est. primary completion 2029-12-31 ·
NCT07341191 ·
CT.gov ↗ What to watch 2030 (2) February 2030 (1) Phase 2 Chronic Lymphocytic Leukemia Not yet recruiting
Est. primary completion 2030-02-28 ·
NCT06367374 ·
CT.gov ↗ What to watch April 2030 (1) Phase 1/2 Acute Myeloid Leukemia Not yet recruiting
Est. primary completion 2030-04-30 ·
NCT07770698 ·
CT.gov ↗ What to watch 2031 (2) February 2031 (1) Phase 3 Chronic Lymphocytic Leukemia Recruiting
Est. primary completion 2031-02 ·
NCT07277231 ·
CT.gov ↗ What to watch July 2031 (1) Phase 2 Chronic Lymphocytic Leukemia Not yet recruiting
Est. primary completion 2031-07-01 ·
NCT07508995 ·
CT.gov ↗ What to watch 2032 (1) February 2032 (1) Phase 3 CLL Active not recruiting
Est. primary completion 2032-02 ·
NCT06073821 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (43) Chronic Lymphocytic Leukemia (15) Acute Myeloid Leukemia (5) Other / comorbidity (23)
Phase 3 (5) Phase 2 (21) Phase 1/2 (9) Phase 1 (8) Appears in other studies (2)